Choudhary Sv, Bisati S, Singh Al, Koley S
Department of Dermatology, Jawaharlal Nehru Medical College, Sawangi, Wardha, Maharashtra, India.
Indian J Dermatol. 2013 Nov;58(6):457-60. doi: 10.4103/0019-5154.119958.
To the best of our knowledge, till date no study comparing the efficacy and safety of terbinafine hydrochloride 1% cream and sertaconazole nitrate 2% cream has been done in localized tinea corporis and tinea cruris.
This clinical trial was carried out to study and compare the efficacy of topical terbinafine hydrochloride 1% cream and sertaconazole nitrate 2% cream in localized tinea corporis and tinea cruris and to know the adverse effects of these antifungal creams.
In this prospective, single blind, randomized control trial with two arms, patient were randomized into two groups Group A (treatment with terbinafine cream) and Group B (treatment with sertaconazole cream). A total of 38 patients were enrolled for the study, 20 patients in group A and 18 patients in group B. But five patients of group A and three patients of group B were lost for follow-ups. Therefore sample size was of 30 patients with 15 patients in group A and group B each.
Patients in group A and B were treated with twice daily topical 1% terbinafine hydrochloride and 2% sertaconazole nitrate cream respectively for a total duration of three weeks. Clinical improvement in signs and symptoms of each clinical parameter, namely itching, erythema, papules, pustules, vesicles, and scaling were graded weekly and clinical cure was assessed. KOH mount and culture was done weekly up to 3 weeks to access mycological cure. Fungal culture was done on Sabouraud's dextrose agar with chloramphenicol and cycloheximide.
Statistical analysis was done using students paired and unpaired t-tests from the data obtained.
Comparison between Group A and Group B for complete cure (clinical and mycological) showed that at the end of 3 weeks both terbinafine and sertaconazole groups had 100% complete cure. When the two groups were compared for complete cure, at the end of 1(st) and 2(nd) week, statistically non-significant results were observed (P = 0.461 and P = 0.679 respectively). However, at the end of 2(nd) week, complete cure rate for terbinafine was 80% as compared to 73.35% for sertaconazole with no statistical significance. In both Group A and Group B, clinically significant local side effects like erythema, swelling, stinging sensation, or increased itching were not noticed. A majority of our patients in both the group showed Trichophyton rubrum followed by Trichophyton mentagrophytes growth on culture. In Group A, 11 patients showed growth of T. rubrum, 2 patients showed growth of T. mentagrophytes, and 1 patient had only KOH test positive. In Group B, 10 patients revealed growth of T. rubrum, followed by growth of T. mentagrophytes in 3 and Microsporum canis in 2 patients. The therapeutic response is more or less same in infection with different species.
The newer fungistatic drug sertaconazole nitrate 2% cream was as effective as terbinafine hydrochloride 1% cream which is one of the fungicidal drugs, though terbinafine hydrochloride 1% cream has higher rates of complete cure at the end of 2 weeks as compared to sertaconazole nitrate 2% cream. Both the drugs showed good tolerability with no adverse effects.
据我们所知,迄今为止尚未有研究比较1%盐酸特比萘芬乳膏和2%硝酸舍他康唑乳膏治疗局限性体癣和股癣的疗效及安全性。
本临床试验旨在研究并比较1%盐酸特比萘芬乳膏和2%硝酸舍他康唑乳膏治疗局限性体癣和股癣的疗效,并了解这些抗真菌乳膏的不良反应。
在这项前瞻性、单盲、随机对照双臂试验中,患者被随机分为两组,A组(用特比萘芬乳膏治疗)和B组(用舍他康唑乳膏治疗)。共有38例患者入组本研究,A组20例,B组18例。但A组有5例患者和B组有3例患者失访。因此,样本量为30例患者,A组和B组各15例。
A组和B组患者分别每天外用1%盐酸特比萘芬和2%硝酸舍他康唑乳膏两次,共持续3周。每周对每个临床参数(即瘙痒、红斑、丘疹、脓疱、水疱和鳞屑)的体征和症状的临床改善情况进行分级,并评估临床治愈情况。每周进行KOH涂片和培养,持续3周以确定真菌学治愈情况。真菌培养在含有氯霉素和放线菌酮的沙氏葡萄糖琼脂上进行。
使用从获得的数据进行的学生配对和非配对t检验进行统计分析。
A组和B组完全治愈(临床和真菌学)的比较显示,在3周结束时,特比萘芬组和舍他康唑组的完全治愈率均为100%。当比较两组的完全治愈率时,在第1周和第2周结束时,观察到统计学上无显著差异的结果(分别为P = 0.461和P = 0.679)。然而,在第2周结束时,特比萘芬的完全治愈率为80%,舍他康唑为73.35%,无统计学意义。在A组和B组中,均未观察到如红斑、肿胀、刺痛感或瘙痒加剧等具有临床意义的局部副作用。两组中的大多数患者培养显示红色毛癣菌生长,其次是须癣毛癣菌生长。在A组中,11例患者显示红色毛癣菌生长,2例患者显示须癣毛癣菌生长,1例患者仅KOH试验阳性。在B组中,10例患者显示红色毛癣菌生长,其次3例患者显示须癣毛癣菌生长,2例患者显示犬小孢子菌生长。不同菌种感染的治疗反应大致相同。
新型抑菌药物2%硝酸舍他康唑乳膏与杀菌药物之一的1%盐酸特比萘芬乳膏效果相同,尽管1%盐酸特比萘芬乳膏在2周结束时的完全治愈率高于2%硝酸舍他康唑乳膏。两种药物均显示出良好的耐受性且无不良反应。